Health
Drugmakers Delay In-Demand Medicines to Evade Biden’s New Pricing Rules
- Roche may hold back drug seeing bigger market down the road
- Industry says pricing constraints hurt innovation, investment
This article is for subscribers only.
Drugmakers are slow-walking products to market to get around President Joe Biden’s plan to lower medication prices.
Companies from Roche Holding AG to biotech Alnylam Pharmaceuticals Inc. are among those delaying or evaluating therapies in light of the government’s new ability to negotiate for lower prices. Firms that normally try to sell drugs as soon as possible are suspending clinical trials and shifting timelines, while patient groups are demanding change.